Solid Tumors Emerging Precision Oncology Map

Clinical outcomes

Safety signals

Key risks include hepatotoxicity, interstitial lung disease or pneumonitis, hypertension, QT prolongation, hemorrhage, hypersensitivity, tumor lysis syndrome, impaired wound healing, and hypothyroidism. Review CYP3A and acid-reducing drug interactions.

Reference: RETEVMO (selpercatinib) U.S. Prescribing Information, revised July 2026; LIBRETTO-001, NCT03157128.

Clinical outcomes

Interim patients with secondary checkpoint-inhibitor resistance treated at the three highest reported dose levels.

Safety signals

Early signals included rash, diarrhea, anemia, and serious treatment-emergent events. The dose and combination safety profile remain under phase 1b evaluation.

Reference: FORTIFY interim update; NCT06270706;

Clinical outcomes

Safety signals

Safety characterization remains early and regimen-specific. Severe treatment-related events were reported, including one grade 4 aplastic-anemia event; use only within the protocol with dose-escalation and organ-specific monitoring.

Reference: Braun et al. Cell Reports Medicine. 2026; NCT05128487;

Clinical outcomes

Safety signals

No dose-limiting toxicities were reported and a maximum tolerated dose was not reached in the published early-phase study. Broader and longer-term safety remain undefined.

Reference: Naing et al. Journal for ImmunoTherapy of Cancer. 2026; NCT05162755;

Clinical outcomes

Safety signals

Potential immune-mediated toxicities include pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, severe skin reactions, and infusion reactions. Organ preservation requires intensive disease-specific surveillance.

Reference: Cercek and colleagues, neoadjuvant dostarlimab program; 2025 update summarized in the

Clinical outcomes

Safety signals

The safety profile remains preliminary. Cytokine-driven and immune-mediated effects require protocol-directed monitoring; no mature population-level risk estimate is established.

Reference: START-001; SITC 2024 abstract 1470 and subsequent expansion update summarized in the

Safety signals

Human safety remains under dose escalation. Protocol monitoring should address cytokine-related inflammatory effects, immune-mediated toxicity when pembrolizumab is used, and agent-specific dose-limiting events.

Reference: WTX-124 phase 1/1b program, NCT05479812;

Safety signals

Early intratumoral therapy requires monitoring for injection-site and systemic inflammatory effects; durvalumab adds immune-mediated toxicity. No mature cross-tumor safety estimate is established.

Reference: mRNA-2752 phase 1 program; Clinical Cancer Research. 2026;

Safety signals

Safety remains protocol-defined in phase 1b. Monitoring must distinguish viral or immune inflammatory effects from chemotherapy- and radiation-related gastrointestinal, hematologic, and local toxicities.

Reference: FORTRESS, NCT06459869;

Safety signals

No mature efficacy or safety profile is established. Protocol care includes lymphodepletion-related cytopenia and infection monitoring plus surveillance for cytokine-release syndrome, neurologic toxicity, and organ-specific inflammation.

Reference: EVEREST-2 development program;

Safety signals

Dose escalation is ongoing and no mature product-specific safety profile is available. Cell-therapy monitoring includes cytokine-release syndrome, neurologic toxicity, prolonged cytopenias, infection, and on-target organ effects.

Reference: Canadian Cancer Trials Group IND246;

Safety signals

Human safety characterization is preliminary. Protocol-level surveillance is required for cytokine-release syndrome, neurologic toxicity, cytopenias, infection, alloimmune effects, and target-related tissue injury.

Reference: FT836 phase 1 program and ASCO 2026 update summarized in the

Clinical outcomes

Single-patient report; these observations are not an objective response rate or a population estimate.

Safety signals

A single case cannot define safety. TCR therapy requires monitoring for cytokine-release syndrome, neurologic toxicity, cytopenia and infection after lymphodepletion, and on-target or off-tumor tissue injury.

Reference: Published compassionate-use PRAME TCR case summarized in the

Safety signals

No mature human safety profile is available. The dose-escalation study is intended to establish dose-limiting toxicities, recommended dose, and organ-specific or payload-related signals.

Reference: CKD-703 phase 1/2a development program;

Safety signals

No mature human safety profile is available. Product-specific dose-limiting, hematologic, hepatic, pulmonary, and other payload-related risks must be defined in the phase 1 study rather than inferred from target expression alone.

Reference: ZW251 / ZD06519 phase 1 development program;

Clinical outcomes

Safety signals

Early combination safety was described as manageable, but remains dose- and schedule-dependent. Monitor for cytopenias, fatigue, gastrointestinal toxicity, and other dose-limiting events under protocol.

Reference: MYTHIC early clinical update summarized in the

Clinical outcomes

Early phase 1/2 evidence; results are not randomized comparisons and should not be interpreted as an approved tumor-agnostic standard.

Safety signals

At the 250 mg once-daily go-forward dose, the most common treatment-related adverse events reported were nausea (26%), anemia (20%), fatigue (19%), dysgeusia (19%), and thrombocytopenia (13%); most were grade 1.

Reference: Vopimetostat (TNG462) phase 1/2 MTAP-deleted solid-tumor program; data cutoff September 1, 2025; ASCO Educational Book 2026 discussion of MTAP-directed synthetic lethality.

Clinical outcomes

Initial phase 1/2 dose-escalation data with short follow-up; these are small, nonrandomized cohorts and require confirmation in later-phase trials.

Safety signals

Most adverse events were grade 1–2. With daraxonrasib, common treatment-related events included rash, stomatitis/mucositis, and diarrhea; there were no related grade 4–5 events or adverse-event discontinuations. Three DLTs occurred in two patients at vopimetostat 250 mg plus daraxonrasib 100 mg. With zoldonrasib, common treatment-related events were nausea and vomiting; no DLTs or related grade 4–5 events were reported.

Reference: Phase 1/2 vopimetostat + daraxonrasib/zoldonrasib program, data cutoff May 28, 2026; NCT06922591; ASCO Daily News, “Targeting MTAP Deletions: PRMT5 and RAS Inhibitors Show Clinical Promise” (2026).

Safety signals

No mature cross-tumor safety profile or efficacy estimate is established. Dose escalation should define hematologic, gastrointestinal, hepatic, and other agent-specific risks without assuming class equivalence.

Reference: BLU-222 and INX-315 development programs summarized in the